CA-VELODYNE-LIDAR
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced it has joined the Qualcomm® Smart Cities Accelerator Program to promote using lidar technology in smart city solutions. By becoming part of the Qualcomm Smart Cities ecosystem, Velodyne will work more closely with Qualcomm Technologies, Inc., governments and solution developers to create smart city applications that improve public services and enhance safety and quality of life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005093/en/
Smart city solutions can use Velodyne’s lidar sensors to measure and monitor conditions in areas such as pedestrian safety, vehicle traffic, parking space management, speed measurement, V2X communications, queue and asset management, security and more. The sensors can collect highly accurate, detailed 3D information about people, vehicles, bicyclists, public spaces and more, while preserving anonymity.
“We are pleased to welcome Velodyne Lidar to the Qualcomm Smart Cities Accelerator Program to implement cutting-edge lidar solutions for a transparent understanding of the smart environment,” said Ashok Tipirneni, Director, Qualcomm Technologies, Inc. and Head of Platform Product Management for Smart Cities. “Velodyne’s lidar sensors and comprehensive 3D data can help equip our Smart Campus and smart city ecosystem members with enhanced safety measures and streamlined operations.”
Until recently, existing camera-based ITS traffic monitoring technologies have been widely used to study traffic flow rates, occupancy, average speed and spot speed. However, as alternative sensors come onto the market, the weaknesses of camera-based approaches become more apparent. For example, cameras have been shown to suffer in low-light conditions, are prone to optical illusions and do not allow for people’s privacy. Velodyne’s lidar sensors provide robust 3D data that allows for superior object detection and tracking in a wide variety of lighting and weather conditions. Furthermore, Velodyne’s sensors do not recognize people’s characteristics, such as their faces or the color of their skin, making it an ideal sensor to support the needs of municipalities without compromising their citizens’ privacy. With Velodyne lidar, smart city applications can advance safety, social welfare and operational efficiency.
As a real-time application demonstration of the significant value that Velodyne’s lidar can bring to smart city applications, Velodyne and Qualcomm Technologies plan to deploy a Velodyne sensor on the Qualcomm Smart Campus. The lidar is intended to be placed indoors to track people as they move around in a public space. The data can help Qualcomm Technologies to detect traffic and usage patterns so the company can better understand utilization rates and make adjustments to facilities. Velodyne worked with Infinite Computer Solutions and Seoul Robotics , an Automated with Velodyne partner, to build the application.
“The combination of Velodyne’s lidar and Qualcomm Technologies edge computing and 5G capabilities creates a powerful asset for developers to make their smart city ideas a potent solution,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Participating in the Qualcomm Smart Cities Accelerator Program will help us connect with governments and solution providers to build lidar-based smart city applications that transform city infrastructure and services.”
Velodyne’s sensors provide rich computer perception data that make it quick and easy for developers, cities, municipalities, government agencies and enterprises to build highly accurate 3D models of any environment. The sensors deliver a high-resolution image that can accurately measure and analyze the environment. Their durability, reliability, power-efficiency and versatility make them ideal solutions for demanding smart city applications.
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “plans,” "estimates," "projected," "expects," "anticipates," "forecasts," "intends," "believes," "seeks," “can,” "may," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005093/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
